Core Viewpoint - Li Auto Inc. continues to strengthen its position in China's new energy vehicle market, achieving significant vehicle deliveries and expanding its infrastructure and product offerings [1][2][4]. Group 1: Vehicle Deliveries and Performance - In February 2026, Li Auto delivered 26,421 vehicles, bringing its cumulative deliveries to 1,594,304 as of February 28, 2026 [1]. - The company powered over 1.45 million charging sessions during the Spring Festival travel peak, with a total charging volume exceeding 42 million kWh [2]. Group 2: Infrastructure and Services - As of February 28, 2026, Li Auto operated 4,054 super charging stations with 22,447 charging stalls across China [3]. - The company has established 539 retail stores in 160 cities and 548 servicing centers in 223 cities [3]. Group 3: Product Development and Innovations - Li Auto rolled out OTA update version 8.3, enhancing the VLA Driver large model, smart cockpit, and smart electric functionality [2]. - The company plans to launch the all-new Li L9 in the second quarter of 2026, expanding its product lineup [2][4]. Group 4: Company Overview - Li Auto is a leader in the new energy vehicle market, focusing on premium smart electric vehicles and extended-range electric vehicles [4]. - The company emphasizes innovation in product, technology, and business models to provide safe and convenient services to families [4].

Company Overview - APEX Tech Acquisition Inc. is a blank check company incorporated in the Cayman Islands, designed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities [5]. Initial Public Offering (IPO) Details - The company announced the closing of its initial public offering of 11,197,131 units at $10.00 per unit, resulting in aggregate gross proceeds of $111,971,310 [1]. - The units began trading on The New York Stock Exchange (NYSE) on February 26, 2026, under the ticker symbol "TRADU" [1]. - Each unit consists of one ordinary share and one right to receive one-fourth (1/4) of one ordinary share upon the consummation of an initial business combination [1]. - Once the units begin separate trading, the ordinary shares and rights are expected to be traded under the symbols "TRAD" and "TRADR," respectively [1]. Underwriters and Legal Counsel - A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering [2]. - Venture Bridge Legal served as the U.S. counsel to the company, while Robinson & Cole LLP served as the U.S. counsel to the representative of the underwriters [2]. Registration and Prospectus Information - A registration statement on Form S-1 relating to the securities was filed with the SEC and declared effective on February 25, 2026 [3]. - The offering was made only by means of a prospectus forming part of the effective registration statement, with copies available on the SEC's website [3].

Core Insights - DBV Technologies presented additional positive data from the Phase 3 VITESSE clinical trial for the VIASKIN Peanut Patch at the AAAAI 2026 Annual Meeting, indicating its potential as a treatment for peanut allergies in children aged 4 to 7 years [2][5] Study Results - The VITESSE study met its primary endpoint, showing a statistically significant treatment effect (p<0.001), with 46.6% of children in the VIASKIN Peanut group meeting treatment responder criteria at 12 months, compared to 14.8% in the placebo group, resulting in a difference of 31.8% [3][6] - Approximately 83% of children treated with the VIASKIN Peanut Patch increased their eliciting dose at month 12, compared to 48% in the placebo group [6][7] - 60% of children treated with the VIASKIN Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group [6][7] - 24% of children on placebo decreased their eliciting dose, while only 6.4% of those treated with the VIASKIN Peanut Patch experienced a decrease [6][7] Treatment Effectiveness - The data suggest a broad and consistent treatment effect of the VIASKIN Peanut Patch across different baseline eliciting dose strata and study population analyses [5] - Among children with a baseline eliciting dose (ED) ≤30 mg, 49.3% were responders versus 14.7% in the placebo group, and among those with a baseline ED = 100 mg, 43.1% were responders versus 14.6% in the placebo group [7] Safety Profile - The VIASKIN Peanut Patch was well tolerated, with most treatment-emergent adverse events being mild local reactions, consistent with previous Phase 3 studies [7] Future Plans - DBV Technologies plans to submit a Biologics License Application (BLA) to the FDA in the first half of the year, supported by the positive data from the VITESSE study [8]

Core Insights - Cogent Biosciences announced additional clinical results from the SUMMIT trial for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), showing significant improvements across primary and secondary endpoints [1][2] Group 1: Clinical Results - Bezuclastinib demonstrated a mean change of -32.0 points in Total Symptom Score (TSS) at 48 weeks, indicating a 56% relative improvement from baseline [5][6] - 99% of patients achieved over 50% reduction in serum tryptase levels, with 83% normalizing their levels [6][11] - Significant improvements were observed across various symptoms, including a 65% reduction in dermatologic symptoms and a 53.6% reduction in neurocognitive symptoms [4][11] Group 2: Safety and Tolerability - Bezuclastinib exhibited a favorable safety and tolerability profile, supporting its potential for chronic use in NonAdvSM patients [7][11] Group 3: Market Position and Future Potential - The company believes bezuclastinib has the potential to become the preferred standard of care for NonAdvSM patients due to its rapid and meaningful symptom improvement [2][10] - The treatment is positioned as the first disease-modifying agent for NonAdvSM, with strong evidence correlating serum tryptase reduction with symptomatic improvement [5][11] Group 4: Inducement Grants - Cogent announced inducement equity awards to three new employees, including nonqualified options to purchase 24,000 shares and 21,000 restricted stock units (RSUs) [8]

Core Viewpoint - Goliath Resources Limited has applied to extend the expiry date of 2,590,673 common share purchase warrants by six months, from March 10, 2026, to September 10, 2026, while maintaining the exercise price at $2.50 per share [1][2]. Company Overview - Goliath Resources is focused on exploring precious metals projects in the Golden Triangle of Northwestern British Columbia, with all projects situated in high-quality geological settings and safe jurisdictions for mining in Canada [3]. - The company completed its largest drill campaign in 2025, totaling 64,364 meters, and is fully funded for a similar-sized drill program in 2026 [3]. - Key strategic shareholders include Crescat Capital, Waratah Capital Advisors, McEwen Inc., a Global Commodity Group, Rob McEwen, Eric Sprott, and Larry Childress [3].

Core Viewpoint - Sonoro Gold Corp. has announced an updated Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA) for its Cerro Caliche gold project, indicating significant potential for a viable mining operation over a ten-year life of mine with increased production rates and favorable economic metrics [1][5]. Updated PEA Highlights - The PEA is based on a base case gold price of $3,500/oz and silver price of $48/oz, showing a pre-tax net present value (NPV8) of $360 million and an internal rate of return (IRR) of 65% [4][13]. - At spot prices of $5,186/oz gold and $88/oz silver, the pre-tax NPV8 increases to $846 million with an IRR of 121% [6][13]. - The project has a gold recovery rate of 72% and a silver recovery rate of 27%, with a total of 459,000 ounces of gold equivalent expected over the life of the mine [6][15]. Mineral Resource Estimate - The updated MRE includes 51,752 k tonnes classified as Measured and Indicated resources, with an average gold grade of 0.37 g/t and silver grade of 3.7 g/t [11]. - Inferred resources are estimated at 8,801 k tonnes with a gold grade of 0.33 g/t [11]. Economic Parameters - Initial capital expenditures (CAPEX) are estimated at $83 million, with sustaining capital costs of $26 million [6][18]. - The cash operating costs are projected at $1,842 per gold equivalent ounce, with all-in sustaining costs (AISC) at $1,902 per ounce [6][30]. Mining and Processing - The mining operation will utilize an open pit, heap leach method, with an initial production rate of 12,000 tonnes per day ramping up to 16,000 tonnes per day [1][18]. - The total tonnes processed over the life of the mine is estimated at 52.8 million, with a strip ratio of 1.6 [15]. Sensitivity Analysis - The PEA includes sensitivity analysis showing how changes in gold and silver prices affect the project's NPV and IRR, indicating robust economic viability under various scenarios [16][20].

Core Insights - Micron Technology has inaugurated a semiconductor assembly and test facility in Sanand, Gujarat, India, marking a significant step in advancing semiconductor manufacturing capabilities in the country [1][2][4] - The facility represents a total investment of approximately $2.75 billion from Micron and its government partners, aimed at meeting the growing global demand for memory and storage products driven by AI [2][3] - The Sanand facility is expected to assemble and test tens of millions of chips in 2026, scaling to hundreds of millions in 2027, thereby enhancing Micron's global assembly and test network [3] Investment and Economic Impact - The investment in the Sanand facility is part of a broader initiative to build a resilient semiconductor ecosystem in India, transitioning the country from a consumer of chips to a global hub for semiconductor manufacturing [2][4] - The facility is designed to meet or exceed Leadership in Energy and Environmental Design (LEED) Gold standards, reflecting Micron's commitment to sustainability and environmental responsibility [5] Workforce Development - Micron is actively developing the next generation of semiconductor talent in India through partnerships with educational institutions and government-sponsored programs, focusing on STEM education and workforce readiness for advanced manufacturing roles [4] Production Capabilities - The Sanand site features over 500,000 square feet of cleanroom space, making it one of the largest single-floor assembly and test cleanrooms globally, and has already begun commercial production [1][3]

Core Insights - CUKTECH has launched the CUKTECH 25SE Power Bank in Malaysia, featuring a 120W output and a capacity of 25,000mAh, available at an introductory price of RM124 [1][7] Product Features - The CUKTECH 25SE is designed as the "value king of high-capacity fast-charging power banks," capable of charging a smartphone over four times or providing a full charge for a thin-and-light laptop, making it suitable for various scenarios such as travel and power outages [3] - It incorporates Adaptive Fast Charging (ADC) technology, ensuring compatibility with major fast-charging protocols including Xiaomi's 120W HyperCharge, PD 100W, and PPS 100W, catering to diverse user needs [4] - The power bank includes a built-in 6A cable that supports up to 120W output and 100W input, enhancing user convenience by eliminating the need for separate charging cables [5] Market Positioning - CUKTECH aims to provide high-quality, cost-effective intelligent charging solutions, emphasizing that premium technology should be accessible to all users in Malaysia [6] - The CUKTECH 25SE Power Bank is available for purchase on official platforms like Shopee and Lazada, coinciding with the 3.3 Mega Sales event, making it an attractive option for consumers seeking quality and performance [7]

Core Insights - The MILESEEY S50 has been awarded the Experts' Choice winner in the Estimating, Project Management, Timekeeping category of the 2026 Innovative Product Awards, highlighting its significant impact on construction workflows [1][4] - The S50 Green Laser Measure, launched in September 2025, is designed for high-precision measurement, indicating strong market reception and potential to redefine digital measurement standards [3][4] Product Features - The S50 features 18 measurement modes, including P2P, and utilizes MILESEEY's patented PowerBurst™ technology, providing a green-beam laser with visibility up to four times greater than traditional red-beam devices [5] - It has an ultra-long measuring range of up to 400 feet and an accuracy of ±1/16 inch, ensuring reliable performance in various challenging environments [5] Company Vision - MILESEEY Group's CEO, Jore Chou, expressed commitment to continuous innovation in green-beam technology, aiming to develop smarter and more intuitive tools for professionals [6] - MILESEEY Tools, established in 2009, focuses on empowering professionals with intelligent tools that enhance precision and efficiency in construction and engineering [7][8]

Core Viewpoint - Fangzhou Inc. has entered a strategic collaboration with Youcare Pharmaceutical Group to enhance chronic disease services through AI-driven solutions, aiming to support China's digital transformation in healthcare [1][2][8] Group 1: Partnership Objectives - The collaboration focuses on two main areas: co-development of digital systems for chronic disease management and expansion of health management services in key therapeutic areas [6][4] - The partnership aims to integrate Youcare's pharmaceutical expertise with Fangzhou's AI capabilities to create a digitally enabled chronic disease management system [6][4] Group 2: Industry Context - China's chronic disease management is shifting from a drug-centered model to a patient-centered approach, necessitating digital transformation in healthcare services [3][8] - The partnership aligns with China's "Healthy China 2030" initiative, emphasizing the importance of integrating AI technology with chronic disease services and pharmaceutical innovation [8][7] Group 3: Company Profiles - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025, specializing in AI-enabled precision medicine [9] - Youcare Pharmaceutical Group is a large-scale conglomerate in the pharmaceutical industry, focusing on drug R&D, manufacturing, and distribution, and is recognized as one of the top 100 enterprises in China [10]